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ABSTRACT: Blocking the bioactivity of allergens is conceptually
attractive as a small-molecule therapy for allergic diseases but has not
been attempted previously. Group 1 allergens of house dust mites
(HDM) are meaningful targets in this quest because they are globally
prevalent and clinically important triggers of allergic asthma. Group 1
HDM allergens are cysteine peptidases whose proteolytic activity
triggers essential steps in the allergy cascade. Using the HDM allergen
Der p 1 as an archetype for structure-based drug discovery, we have
identiﬁed a series of novel, reversible inhibitors. Potency and
selectivity were manipulated by optimizing drug interactions with
enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes
required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic
responses by targeting just a single component, namely, Der p 1. Our ﬁndings suggest that these inhibitors may be used as novel
therapies for allergic asthma.
■ INTRODUCTION
At the heart of the clinical management of asthma lies a
paradox: despite eﬃcacious and safe therapies (e.g., β2 agonist
bronchodilators, inhaled corticosteroids, antileukotrienes, and
an anti-IgE monoclonal antibody), the condition remains
poorly controlled and its prevalence continues to increase.1,2
The multiple factors underlying this paradox highlight a
signiﬁcant unmet need which might be better addressed by a
completely diﬀerent approach. Current standard of care in
asthma is directed at downstream eﬀector mechanisms, and the
medicines involved act primarily by relieving symptoms. For
novel therapies in development, target selection has been
primarily driven by a focus on deeper understanding of the
eﬀector pathways of asthma, with the hope that new
nonsteroidal interventions will reduce both the risk of disease
exacerbations, which is the major goal of clinical management,
and the potential for adverse events. However, experience
shows that only limited success has been achieved by targeting
individual downstream eﬀectors in asthma, highlighting the
need for new approaches.
For any condition, an alternative to symptom management is
to target the major trigger or root cause. However, asthma is a
complex spectrum of conditions rather than a homogeneous
disease and on ﬁrst inspection such an approach seems
unfeasible. Asthma may be broadly divided into nonallergic and
allergic types, with the latter, triggered by inhaled environ-
mental allergens, predominating. Two pieces of epidemiological
evidence suggest that design of an intervention directed toward
a trigger of allergic asthma could be surprisingly tractable. First,
a succession of studies highlight that, globally, the most
important providers of allergen triggers are house dust mites
(HDM).3−12 Second, sensitization to HDM precedes the
development of sensitization to allergens from unrelated
sources.13,14 Mechanistically, this longitudinal relationship
exists because HDM facilitate sensitization to other agents by
providing essential collateral priming events on which other
allergens depend.
HDM are sources of more than 20 denominated allergen
groups,15 with those of group 1 being of particular interest
because of their abundance, allergenicity, and their functional
properties which promote sensitization to themselves and other
allergens.15−24 Sensitization to HDM allergens occurs through
inhalation of this animal’s fecal pellets, which, when they impact
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upon the airway mucosa, hydrate and release their contents.
The group 1 allergens (e.g., Der p 1, Der f 1, Eur m 1) of the
various HDM species form a distinct subfamily of C1 cysteine
peptidases25 whose sequences are suﬃciently identical that
targeting them with a single agent is a realistic possibility.22
Two general peptidase-dependent mechanisms have been
identiﬁed by which group 1 HDM allergens promote allergic
sensitization and asthma. The ﬁrst is their ability to cleave
epithelial tight junctions by proteolytic attack on the trans-
membrane adhesion domains of occludin and claudin family
proteins.24,26 This cleavage results in the epithelial barrier
becoming leaky, increasing the probability of contact of any
allergen with dendritic antigen-presenting cells and permitting
the migration of these cells, along with secondary eﬀector cells,
into the airway lumen.6,27,28 Their second general mechanism
as proteases is to activate signal transduction pathways of innate
immunity which release chemokines and other mediators (e.g.,
IL-13, IL-33, TSLP, IL-25, CCL-20)16,18,29 that are known to
recruit the necessary eﬀector cells and promote a TH2 bias to
immune responses.6,18,23,29−31 Signiﬁcantly, evidence suggests
that some of these innate immune mechanisms are the focus of
important genetic predispositions for allergic asthma.32
Given the importance of HDM sensitization as a trigger for
asthma and the increasing recognition that the peptidase
activity of group 1 HDM allergens plays an important role in
both its initiation and maintenance, the aim of our program was
to develop small-molecule inhibitors of these pivotal allergens.
We call these new drugs “allergen delivery inhibitors” (ADIs),
and it is our hypothesis that an ADI compound would provide
an eﬀective inhaled treatment for patients suﬀering from
allergic asthma. The compounds disclosed herein are the
subject of a patent disclosure.33
■ RESULTS AND DISCUSSION
Identiﬁcation of Reversible Der p 1 Inhibitors. Prior to
the commencement of our program, the only reported
inhibitors of Der p 1 were irreversible acyloxymethyl ketone
inhibitors (Figure 1).34 Given that asthma treatment will
require chronic drug administration, we considered that
compounds having an irreversible mechanism of action were
inherently lacking in developability because of their potential to
elicit adverse eﬀects. We therefore sought to replace the
irreversible binding motif with functional groups that could
form a fully reversible covalent bond with the active site
cysteine residue. An investigation of amino-ketones aﬀorded
compounds with initially encouraging potency against Der p 1,
but we were unable to optimize inhibitory activity beyond that
shown by compound 3. To enhance binding to the active site
cysteine residue, we therefore examined alternative groups,
including the corresponding pyruvamide analogues. This
rapidly led to the identiﬁcation of compound 5, which became
the starting point for our discovery program (Figure 1).
Low molecular weight peptides are often characterized by
poor oral bioavailability. This has been attributed to their
propensity for proteolytic cleavage, and the presence of a high
proportion of hydrogen bond donors and acceptors, in
conjunction with a relatively ﬂexible scaﬀold; factors likely to
hinder passive absorption in the gut. Conversely, these
Figure 1. Reversible Der p 1 inhibitors were derived from a series of irreversible inhibitors by modifying the cysteine binding motif. This led to the
identiﬁcation of pyruvamide inhibitor 5.
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properties may be beneﬁcial for an inhaled drug as they would
minimize absorption of any inadvertently swallowed portion of
a dose, thereby limiting adverse systemic eﬀects. In our view,
these considerations made a peptidic scaﬀold an ideal template
for the design of an inhaled Der p 1 inhibitor.
To obtain in vivo eﬃcacy that was compatible with delivery
from a range of inhaler devices, we required a compound with
high inhibitory potency against Der p 1. Upon the basis of
empirical estimates of target exposure, we therefore set a
template IC50 ≤ 20 nM for the target. While compound 5
fulﬁlled this criterion, a developable candidate requires other
features that impact on in vivo eﬃcacy, notably those properties
that would aﬀect the retention of the compound at the site of
action: permeability, lipophilicity, and stability in the lungs.
Additionally, increasing the intrinsic selectivity of our initial
lead over closely related human cysteine peptidases, notably
cathepsin B (Cat B) (Figure 1), was desirable because intrinsic
selectivity combined with low systemic exposure would reduce
the risk of oﬀ-target events. This risk would be subject to
further mitigation because of the entirely extracellular
interaction between target and inhibitor, whereas the potential
oﬀ-target enzymes have largely intracellular dispositions which
would require compounds to be highly membrane permeant for
enzymes to be at risk of inhibition. Pharmaceutical properties
were also taken into account early in the program so as to
generate compounds that would be suitable for use in a dry-
powder inhaler (DPI), our preferred device. The requirement
to be able to consistently produce particles of optimal
respirable size places stringent constraints on the solid-phase
behavior of compounds that are to be delivered by DPI. For
example, the need to be compatible with micronization requires
a stable, nonhygroscopic crystalline form with a melting point
>100 °C. Aqueous solubility was required to balance adequate
drug dissolution for eﬃcacy with an enduring eﬀect while
avoiding the potential for irritancy associated with low solubility
compounds. Compound 5 lacked selectivity and was
extensively (>50%) degraded by airway macrophages over a 2
h period, suggesting that its duration of action in vivo would be
insuﬃcient. However, its potency and the scope for structural
variation suggested it was a promising lead for optimization.
Synthetic Chemistry. Pyruvamide-motif inhibitors were
synthesized from the corresponding α-hydroxy amides (7) by
oxidation with the Dess−Martin periodinane reagent (Scheme
1). The α-hydroxy amide intermediates were constructed by
two synthetic approaches: either a modiﬁed Passerini reaction35
(route A) or the use of cyanohydrin chemistry (route B). Both
routes required capped dipeptide acids (6), produced either by
solid- or solution-phase synthesis. Solid-phase synthesis was
carried out using standard Fmoc chemistry on Wang resin.36 In-
solution chemistry used a stepwise process which involved, as a
typical ﬁrst step, the coupling of a P2 amino acid ester (11) with
a Boc-protected P3 amino acid (10) under low-temperature
Scheme 1. General Route to Pyruvamide Inhibitors of Der p 1a
a(i) Dess−Martin periodinane, DCM.
Scheme 2. General Procedure for the Solution-Phase Synthesis of Dipeptide Acidsa
a(i) iBuOCOCl, N-methylmorpholine, −40 °C, THF; (ii) TFA, DCM or 4 N HCl/dioxane; (iii) P4-CO2H, TBTU, DIPEA, DCM; (iv) LiOH,
THF/H2O.
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mixed-anhydride coupling conditions to avoid epimerization of
the P3 chiral center (Scheme 2).
For route A, the dipeptide acids (6) were typically coupled
with the appropriate amino alcohol (13) followed by oxidation
to give the corresponding aldehyde (14). A modiﬁed Passerini
reaction was then used to produce the α-hydroxy amide
(Scheme 3).35 For route B, a variety of α-hydroxy amides (7)
were synthesized by coupling β-amino-α-hydroxy amides (15)
with dipeptide acids (6) under similar conditions to those
previously described (Scheme 3). The β-amino-α-hydroxy
amides (15) were made in seven steps from Cbz-protected
valine 16 (Scheme 4).
Finally, some compounds were made by routes C and D,
each being a variation on route B where the order of events was
changed to aid the synthesis of particular analogues (Scheme
1).
Modeling the Binding Mode to Der p 1. To assist the
design of analogues of compound 5, a computational model
was constructed based on the crystal structure of Der p 1 (PDB
code 2AS8) and on the structures of a number of peptidic
inhibitors bound to the C1 family of clan CA peptidases (PDB
codes 1TU6 and 2BDL). Compound 5 was built and
minimized within the active site of the Der p 1 crystal
structure. The electrophilic carbonyl of the pyruvamide was
positioned to form a covalent interaction with the catalytic
cysteine residue (Cys 34), while the peptide backbone of 5 was
oriented to follow a similar trajectory to that of the other
peptidic inhibitors. This minimized structure revealed a number
of putative hydrogen-bonding interactions which anchored
compound 5, thereby allowing the side chains to interact with
the speciﬁcity pockets of the enzyme. On the basis of this
binding model, we propose that the amide carbonyl of the
pyruvamide unit interacts with the backbone NH of Cys 34, the
NH of the P1 subunit is able to form an interaction with the
carbonyl of Tyr 169, and the P2 subunit forms a donor−
acceptor pair with the backbone carbonyl and NH of Asp 74
(Figure 2a).
Improving Selectivity. Signiﬁcant oﬀ-target activity of
compound 5 against Cat B was revealed by counter-screening
against human cysteine peptidases, notably certain members of
the C1 family. We therefore investigated SAR around
compound 5 with the aim of improving the selectivity proﬁle
(Table 1). We established that the P′ cyclohexyl group could be
replaced with a benzyl group without a signiﬁcant eﬀect on Der
p 1 potency or selectivity (for comparison see 19 and 20;
similar eﬀects seen for other analogues, data not shown), so
these two groups were used interchangeably for SAR
comparisons. As the pyruvamide motif has the potential to
interact indiscriminately with nucleophilic cysteine or serine
residues of other peptidases, we hoped that increasing the steric
bulk of the P1 substituent would hinder nonspeciﬁc
interactions. Increasing the branching at P1 to iso-propyl (19)
retained inhibitory potency on Der p 1 but did not signiﬁcantly
improve selectivity over Cat B. It did however improve
Scheme 3. General Procedures for the Synthesis of α-Hydroxy Amide Tripeptidesa
a(i) iBuOCOCl, N-methylmorpholine, −40 °C, THF; (ii) Dess−Martin periodinane, DCM; (iii) P′N+C−, pyridine, TFA, DCM.
Scheme 4. General Procedure for Synthesis of β-Amino-α-hydroxy Amide Intermediatesa
a(i) N-Methyl-O-methyl-hydroxyl amine, EDC, DIPEA, DCM; (ii) LAH, THF; (iii) NaHSO3, NaCN, H2O/THF; (iv) 6 N HCl, dioxane, 100 °C;
(v) Boc2O, Et3N, MeOH; (vi) diphosgene, H2NP′, DCM; (vii) TFA, DCM or 6 N HCl dioxane, THF.
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resistance to processing by airway macrophages, with ∼70%
remaining unchanged after 2 h. The iso-propyl group was
retained for further investigations because further branching to
tert-butyl (21) reduced the potency against Der p 1. Of further
note, removal of the P1 substituent resulted in a 10−20-fold
drop in Der p 1 potency (see Supporting Information,
Appendix 5, compound 76).
Comparison of the reported crystal structures of Der p 1 and
Cat B revealed that the S3 pocket is more capacious in Der p 1
than in Cat B, mainly due to the presence of a Thr in Der p 1
(Thr 74) instead of Tyr in Cat B (Tyr 75). Cathepsins S (Cat
S) and K (Cat K) also possess similar large groups at this
position (Phe 70 in the case of Cat S and Tyr 67 in the case of
Cat K). We hypothesized that increasing the steric bulk at P3
would increase selectivity with respect to these enzymes
(Figure 2c,d), and it was therefore pleasing to ﬁnd that
switching from benzyl (5) to tert-butyl (22) increased
selectivity over Cat B while maintaining good inhibitory
potency on Der p 1. Similarly, introducing geminal-dimethyl
substitution onto the benzyl group (23) reduced inhibitory
Figure 2. Model of compound 5 bound to Der p 1 (PDB: 2AS8) and Cat B (PDB: 1GMY). (a) Proposed binding mode of compound 5 (green) to
Der p 1 active site. (b) Proposed binding mode of compound 5 to Cat B active site. (c,d) Proposed incorporation of dimethyl group (pink) as part of
the P3 substituent bound to Der p 1 and Cat B respectively. The bulky P3 residue is anticipated to clash with Tyr 75 in Cat B.
Table 1. Impact of Modifying P1, P2, and P3 Groups on Der p 1 Potency and Selectivity over Cat B
compd no. P1 P2 P3 P′ Der p 1 IC50 (nM) Cat B IC50 (nM)
5 n-Bu Me benzyl cyclohexyl 8 ± 1 17 ± 2
19a i-Pr Me benzyl cyclohexyl 18 ± 2 52 ± 5
20 i-Pr Me benzyl benzyl 12 ± 2 50 ± 5
21 t-Bu Me benzyl cyclohexyl 9167 ± 880 NDb
22 i-Pr Me t-Bu cyclohexyl 14 ± 3 378 ± 27
23 i-Pr Me C(Me)2Ph benzyl 42 ± 6 446 ± 11
24 i-Pr n-Pr benzyl cyclohexyl 164 ± 24 67 ± 1
aContains ∼30% of P1 R epimer.
bND = not determined.
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potency against Cat B with only a modest impact on Der p 1
activity. Compound 22 also showed resistance to airway
macrophages, with no signiﬁcant degradation observed over 2
h.
Further modeling suggested that the S2 pocket was shallow in
Der p 1 compared to cathepsins B, K, or S; eﬀective inhibitors
of these enzymes tend to have groups larger than methyl at this
position.37−39 Consistent with these observations, the methyl
substituent at P2 generally provided the best balance of potency
and selectivity for Der p 1 (19 vs 24).
Modiﬁcation of Molecular and Physicochemical
Properties. Preliminary investigations into the P1, P2, and P3
positions had shown that we could obtain good inhibitory
potency against Der p 1 and signiﬁcantly improve the selectivity
over Cat B. We next turned to the N and C terminal groups
with the aim of modifying physicochemical properties to
optimize the endurance and pharmaceutical properties of
inhibitors. Simultaneously, we hoped to take advantage of any
preferences shown in the S4 and S′ pockets to further enhance
Der p 1 potency and selectivity with respect to Cat B.
A number of chemical design philosophies have been
adopted to enhance the duration of action of small-molecule
drugs aimed at other respiratory targets.40,41 Approaches
considered potentially applicable to ADIs involved the
incorporation of features to confer either low permeability or
increased binding to lung tissue. Permeability can be reduced
by increasing molecular weight and/or PSA, whereas lung tissue
retention may be enhanced by combining increasing lip-
ophilicity with a basic or quaternary ammonium group.
However, because it was uncertain how eﬀective or well-
tolerated any of these tactics would be in the case of Der p 1
inhibitors, we decided to modify their molecular and physical
properties as widely as possible, thereby maximizing the scope
to manipulate their in vivo and pharmaceutical behavior.
A variety of groups were investigated in the P4 position.
Additional small lipophilic substituents on the phenyl ring were
tolerated (data not shown), as were fused rings which could be
used to increase molecular weight and log D. Furthermore,
some of these groups gave improved selectivity over Cat B
(compounds 25, 26, and 27, Table 2). Replacement of the
Table 2. Impact of Modifying the P4 Substituent on log D, Der p 1 Potency, and Selectivity over Cat B
aContains ∼30% of P1 R epimer. bND = not determined. cSingle determination measured as described in Supporting Information.
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Table 3. Impact of Modifying P′ Substituent on log D, Der p 1 Potency, and Selectivity over Cat B
aContains ∼30% of P1 R epimer. bND = not determined. cSingle determination measured as described in Supporting Information.
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phenyl group with 5- or 6-membered heterocycles reduced log
D but, with the exception of the 4-pyridyl group (29), these
decreased the potency against Der p 1. It was also possible to
incorporate a basic center in the form of an N-methylpiperidine
group (31) which could be quaternized to give 32, which as
expected showed excellent aqueous solubility (∼1.6 mmol
when shaken in PBS7.4 for 2 h). The S4 pocket in Der p 1 is
surrounded by a number of Tyr residues (Tyr 169, Tyr 216,
Tyr 218), and we speculate that the positively polarized N-
methyl hydrogen atoms of 32 are able to make favorable
interactions with these residues, thereby resulting in a potent
Der p 1 inhibitor.
Having shown that cyclohexyl and benzyl gave good activity
in the P′ position, we next turned to exploration of the SAR in
this region. Because the parent compounds, such as 22, were
lipophilic, we initially focused on reducing log D because this
would increase aqueous solubility and mitigate any potential
risk of irritancy arising from the accumulation of poorly soluble
compounds in the lung. Replacement of the C-4 cyclohexyl
carbon with a heteroatom lowered both Der p 1 and Cat B
inhibitory activity and was not pursued further (Table 3, 33 and
34). It transpired that a more successful means of lowering log
D was to reduce the ring size. Replacement of the cyclohexyl
group (22) with a cyclopropyl group (35) reduced the
measured log D by ∼1.5 log units while maintaining high
potency against Der p 1 and selectivity over Cat B, whereas
removal of the P′ group caused attrition of selectivity even
though potency was acceptable (36). However, simple
substitution with a methyl group was suﬃcient to restore
selectivity (37). Regardless of these ﬁndings, we discovered that
the synthesis of P′ benzyl analogues was a more fruitful
approach to the modiﬁcation of physiochemical properties and
the optimization of both potency and selectivity. In general,
lipophilic groups in the para position were less active than more
polar groups, especially those containing a hydrogen bond
donor. In particular the introduction of a p-SONH2 group, as in
compound 39, gave high Der p 1 potency and excellent
selectivity over Cat B. Introduction of an α-methyl group
showed a preference for the R enantiomer (42). Basic groups
could also be appended to the phenyl ring as shown by
compound 41.
To further probe the SAR of the P′ pocket, we elected to
explore a series of glycinamide analogues, reasoning that the
glycinamide moiety could mimic the peptidic backbone of a
substrate molecule and that the amide substituent would allow
us to modify the molecular and physical properties.
Furthermore, this subseries would have an increased PSA,
thereby reducing compound permeability in both the lung and
the gut. Serendipitously, this was an eﬀective way of removing
the undesired Cat B activity. Compound 45, containing a basic
motif, showed excellent Der p 1 inhibitory activity and good
selectivity over Cat B. Moreover, combining this modiﬁcation
Figure 3. (a) Plot of PSA (Å2) versus measured log D7.4 for compounds used to explore the eﬀects of physiochemical properties on in vivo eﬃcacy.
Symbols denote the anticipated ionization state at pH 7.4: circle (neutral), square (positively charged basic center), and diamond (positively charged,
quaternary ammonium). (b) Percentage reduction in the number of eosinophils recovered by BAL 48 h after challenge of nonsensitized rats with a
natural mixture of HDM allergens following a single intratracheal dose of test compound 2 h prior to challenge. Compounds were dosed at a
drug:target molar ratio of 15:1 (compound 38) or 50:1 (other compounds). (c) Compound 52 exempliﬁes the endurance of protection (>6 h) by
quaternary amines. Data are shown as the percentage reduction in BAL eosinophil numbers following HDM allergen challenge after administration
of a single intratracheal dose of 52 (67 nmol/kg) administered at the stated times prior to HDM allergen challenge. In (b) and (c), data are mean
values ± SE, with 10 animals per treatment group. *P < 0.001 (1-way ANOVA) compared to controls which were not treated with 52.
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with a tert-butyl group in P3 resulted in compound 48 that was
both potent against Der p 1 and which showed no signiﬁcant
inhibition of Cat B at 2.5 μM. Alternatively, replacing the N-
methyl group with a bulkier iso-propyl group (49) or
introducing a substituent on the α position of the glycinamide
(50), reduced inhibition of Cat B without the need to introduce
the tert-butyl group at P3. As can be seen from Table 3,
glycinamides that were potent against Der p 1 spanned a range
of lipophilicity. Additionally, it was possible to convert the
piperazine group to a quaternary ammonium compound (52)
with good Der p 1 activity and excellent selectivity over Cat B.
To further examine the selectivity of inhibitors produced by
P′ variation, compounds were counter-screened against a wider
panel of proteases and it was pleasing to see that good
selectivity was attained over a diverse range of targets. As
general exempliﬁcation of a compound which displays
encouraging potency against the Group 1 HDM peptidase
allergens, data for compound 38 are presented in Appendix 7 of
the Supporting Information.
Pharmaceutical Properties. A key goal of the program
was to produce potential candidate drugs with stable crystalline
forms compatible with delivery by DPI and with conﬁdence
that they would be compatible with other devices. Several
approaches were taken to increase the likelihood of obtaining
crystalline compounds. However, it was diﬃcult to predict with
conﬁdence which would crystallize; after establishing a viable
approach, approximately half of the compounds examined
crystallized readily, and it is probable that others could be
crystallized with further eﬀort. Tactics used to favor crystallinity
are described in the Supporting Information. The fact that
satisfactory crystalline properties were common and associated
with molecules whose proﬁles could be manipulated by
structural alterations at multiple locations meant that we were
able to prosecute the program with conﬁdence that all of the
required characteristics for a candidate drug were achievable
within this series.
Eﬃcacy in Vivo. Having demonstrated that it was possible
to obtain potent, selective inhibitors of Der p 1 spanning a
range of physicochemical properties and that no overriding
issues with crystallinity existed, experiments were carried out to
elucidate which features were most strongly correlated with in
vivo eﬃcacy. All of the compounds chosen for this work
showed no degradation when incubated with rat airway
epithelial cells or airway macrophages for 2 h, thereby
minimizing metabolic instability as a variable in these studies.
A series of similarly potent compounds with a range of
measured log D7.4 values and PSA values (Figure 3a) were
chosen for study in rats challenged with a natural mixture of
allergens from Dermatophagoides pteronyssinus, i.e., a diverse
mixture containing the full spectrum of HDM allergens
including our drug target, Der p 1. We had previously
discovered that when delivered by intratracheal aerosol to
rats, the proteolytic activity of Der p 1 in this mixture recruited
inﬂammatory cells to the airways in the absence of prior
sensitization because the proteolytic activity triggered innate
immune responses. The nature and time-course of this cell
recruitment was similar to that which occurs in animals
sensitized to HDM but was of smaller magnitude. As a ﬁrst
step, we therefore exploited this ﬁnding of a peptidase-
dependent innate response to compare the activity of selected
Der p 1 inhibitors. In brief, this model involved intratracheal
aerosolization of a solution of the test compound into rats using
a Penn-Century device, followed 2 h later by challenge with a
mixture of HDM allergens delivered by the same method.
Figure 4. Eﬀect of single dose pretreatment with compound 32 (12 μg/kg; 18 nmol/kg) on the recruitment of cells to the airways 48 h following
challenge with mixed HDM allergens in sensitized BN rats. The compound was administered 2 h prior to HDM allergen challenge. (a) Data for total
nucleated cells recovered by BAL; (b) corresponding data for eosinophils. Results are shown as mean ± SE. Treatment groups comprised 10 animals.
*P < 0.01 versus vehicle (veh)-challenged animals sensitized to HDM. **P < 0.001 versus animals pretreated with vehicle and then challenged with
mixed HDM allergens (1-way ANOVA).
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Bronchoalveolar lavage (BAL) was performed 48 h after
allergen challenge as the optimal time to evaluate any eﬀects on
the recruitment of eosinophils (data not shown). The
compounds under investigation contained a range of groups
that would be expected to be neutral or positively charged at
physiological pH. The percentage inhibition of eosinophil
recruitment when challenged with the HDM allergens was
recorded (Figure 3b). There was a clear trend toward more
lipophilic compounds showing better eﬃcacy (compare
compounds 27, 29, and 38 to compounds 45, 47, and 53).
Good eﬃcacy was also achieved for the quaternary ammonium
compounds 32 and 52 with good endurance of action (>6 h
protection from a single dose) evident for both (Figure 3c).
Further details of the duration of protection achieved with a
selection of inhibitors are presented in Appendix 8 of the
Supporting Information.
Demonstration of potency and endurance of action against
the HDM allergen target in the innate response model led us to
investigate eﬃcacy in an IgE-dependent context in animals
actively sensitized to a mixture of HDM allergens. Figure 4a
shows that a single dose of compound 32 administered 2 h
prior to allergen challenge signiﬁcantly blunted the increase in
total nucleated cells recoverable from the airways by BAL. At
the 48 h sampling point, the majority of this reduction was
accounted for by the marked inhibition of eosinophil
recruitment (Figure 4b).
Systemic Exposure. The PK behavior of a range of
compounds was measured in rats to assess the extent of any
systemic exposure which might lead to side eﬀects. Systemic
exposure following drug delivery by inhalation can arise from
the portion of the dose that is inadvertently swallowed, creating
the potential for both on- and oﬀ-target systemic eﬀects, so part
of our design strategy was to minimize oral absorption. Further
studies are planned to assess the extent of systemic exposure
directly from the lung.
For existing antiasthma medicines, the systemic eﬀects being
avoided are primarily on-target actions. One approach to avoid
systemic eﬀects is to introduce a metabolic “soft-spot” so that
biotransformation occurs predictably to an inactive metabolite.
In this program, the therapeutic target is nonhuman and it is
found only in the airways after inhalation, so systemic exposure
to ADIs is concerned solely with oﬀ-target eﬀects. Although oﬀ-
targets can be predicted by homology with the therapeutic
target, unexpected eﬀects of both the parent drug and its
metabolites remain a possibility. Our preferred path was
therefore more general, relying on the minimization of free
drug levels in plasma by varying PPB and oral bioavailability,
alone or in combination. Selected compounds were therefore
proﬁled using a 5 mg/kg oral dose in fed rats with the aim of
generating compounds with a free concentration Cmax < 100
nM. The oral dose was chosen primarily to allow accurate
quantitative analysis because in practice the actual dose of an
inhaled compound would be >300-fold less. In these studies, a
number of compounds showed encouragingly low levels of free
drug (Table 4). For the smaller lipophilic analogue 35, high
oral bioavailability was observed, but for higher MW analogues
such as 38 and 28, the combination of reduced oral
bioavailability and high PPB resulted in negligible levels of
free drug even at doses more than 2 orders of magnitude higher
than those that would be given therapeutically. As anticipated,
the quaternization of amines, as demonstrated by compounds
32 and 52, was a particularly eﬀective means of reducing oral
absorption.
Further Optimization. The P4 and P′ substituents were
subsequently varied to generate a wider range of compounds
with the desired potency/selectivity proﬁle (Table 5). The
most promising compounds from the entire compound set
were subsequently evaluated in depth using in vivo models.
With low systemic exposure, excellent Der p 1 potency and
selectivity, high aqueous solubility, and eﬃcacy beyond 6 h,
compounds 32 and 52 exemplify one approach to the design of
Der p 1 inhibitors (Table 6). Furthermore, Table 6
demonstrates that by using Der p 1 as the chemical design
template and the screening target, it was possible to obtain
potent inhibitors of an orthologous group 1 HDM allergen
from another HDM species, D. farinae, conﬁrming their
behavior as a single drug target.
■ CONCLUSION
This program has identiﬁed compounds which create an
innovative approach to the treatment of allergic asthma.
Unusually, the therapeutic target is nonhuman, it is contacted
by inhalation, and its engagement with an inhibitor is
extracellular, features which are attractive for chemical design.
Starting from leads which act irreversibly, we designed potent,
reversible inhibitors of Der p 1. Clinically, Der p 1 is widely
considered to be archetypal of group 1 allergens from all HDM
species and is used as a surrogate measure of environmental
exposure to HDM generally. Immunological reactivity to group
1 HDM allergens is globally prevalent and is found in >90% of
patients who are allergic to HDM.9,15,42 Collectively, these
strategic factors make HDM the major domestic trigger of
asthma attacks. Our work validates Der p 1 as an archetype for
drug design because we were able to demonstrate the principle
that leading compounds were equally eﬀective as inhibitors of
the orthologous group 1 allergen from another clinically
signiﬁcant HDM species. The cysteine peptidase activity of Der
p 1 and, by inference, other group 1 HDM allergens, is of
functional signiﬁcance to the development of allergic disease
through general mechanisms which are targeted by these new
inhibitors.22 We call the new compounds “allergen delivery
inhibitors” to reﬂect the sentinel events which are blocked by
this intervention.
Candidate ADIs were generated by optimizing interactions
with the binding pockets and improvements in selectivity were
largely achieved by modifying the substituents interacting at P3
and P′. In the case of the P3 position, this can be rationalized by
the presence of a more open substrate-binding pocket in Der p
1. Additionally, by modifying their terminal groups, we have
demonstrated that Der p 1 inhibitors with a wide range of
physiochemical properties can be identiﬁed, allowing the
impact of such properties on in vivo eﬃcacy to be explored.
These studies show that lipophilic compounds, and those
Table 4. Levels of Exposure Following Oral Dosing to Rats
compd
no. F %a
Cmax 5 mg/kg po
(nM) PPB (%)
free conc Cmax
(nM)
35 90 ± 11 1136 ± 268 84.5 ± 0.6 176 ± 0
38 33 ± 8 732 ± 3 96.0 ± 0.2 29 ± 0
28 20 ± 1 663 ± 26 98.0 ± 0.1 11 ± 0
52 0 ± 0 7 ± 2 63.5 ± 0.7 3 ± 0
32 1 ± 0 20 ± 13 61.2 ± 0.2 8 ± 0
aBioavailability based upon comparison with a 1 mg/kg (1−2 μmol/kg
according to compound) iv dose. Data are mean ± SE (n = 3 animals/
compound).
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incorporating a quaternary ammonium group, display superior
in vivo eﬃcacy in a rodent HDM allergen challenge model. A
number of the compounds have a high-melting crystalline form
and show low levels of exposure when dosed orally, two further
properties which are desirable in an inhaled drug.
Epidemiological studies highlight the importance of HDM
allergy as both an asthma trigger and a facilitator of allergic
sensitization generally.42 This central importance of HDM and
their allergens accords with the sentinel roles that innate
mechanisms play in the development of allergic asthma through
the activation of pathogen-associated molecular patterns
(PAMPs) and danger-associated molecular patterns (DAMPs)
which are linked to the expression of TH2-polarized adaptive
immunity.15 HDM, with their environmental pervasiveness and
extensive repertoire of allergens of diverse biological activity,
are understandably decisive regulators of innate responses
operating through such mechanisms. While the exact nature of
the collateral priming mechanisms activated by HDM exposure
is incompletely understood, compelling evidence implicates
cysteine peptidase group 1 allergens as key compo-
nents.6,16,18,22−24,37 This is supported by our in vivo experi-
ments where we show, for the ﬁrst time, that the targeted
inhibition of a group 1 allergen by suitably optimized
compounds substantially reduces cellular inﬂammation follow-
ing challenge with a mixture comprising more than 20 diﬀerent
allergens. This suggests that ADIs have the potential to
inﬂuence inter alia a broad spectrum of innate pathways which
form the general mechanism which underpins the development,
maintenance, and, ultimately, escalation of allergic asthma. The
emergence of promising candidates from this program,
including one nominated for development, will enable
evaluation of a new therapeutic approach to allergic asthma
based upon treating its root cause rather than by amelioration
of its symptoms.
■ EXPERIMENTAL SECTION
The syntheses of key compounds are described below. All
commercially available solvents and reagents were used without
further puriﬁcation unless otherwise noted. NMR spectra were
measured with a Bruker DRZ 400 MHz spectrometer; chemical shifts
are expressed in ppm and are aligned relative to the residual solvent
peak, e.g., 2.5 ppm for DMSO. Coupling constants (J) are recorded in
Hz. The purity of test compounds was determined by reverse-phase
Table 5. Further Optimization of the P4 and P′ Groups with Respect to Der p 1 Potency and Selectivity over Cat B
Table 6. Overall Proﬁle of Compounds 32 and 52
compd no. Der p 1a (nM) Der f 1a (nM) Cat Ba (nM) Cat Sa (nM) F (%)b reduction in innate BAL eosinophil response (%)c
32 6 ± 1 4 ± 0 274 ± 44 108 ± 17 0.6 ± 0.2 58.7 ± 11.3d
52 17 ± 2 11 ± 1 >2500 114 ± 7 0 ± 0 65.6 ± 7.1d
aIn vitro enzymatic assays were performed as described in Experimental Section. bBioavailability was determined in groups of 3 nonfasted Sprague−
Dawley rats as described in Supporting Information. Data are mean ± SE (n = 3). cCompounds were dosed as intratracheal aerosols 6 h prior to
challenge of groups of 10 animals with the HDM allergen mixture. Dose delivered to each animal was ∼40 μg/kg at a drug:target molar ratio of 50:1.
dMean ± SE, in groups of 10 animals. P < 0.001 compared to control (one-way ANOVA).
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm501102h | J. Med. Chem. 2014, 57, 9447−94629457
LC-MS using an analytical C18 column (Phenomenex Luna C18 (2)
150 mm × 4.6 mm, 5 μm), using a diode array detector and an A:B
gradient starting from 95% A:5%B at a ﬂow rate of 1.5 mL/min, where
eluent A was 0.1% formic acid/H2O and eluent B was 0.1% formic
acid/MeCN or 0.1% formic acid/MeOH. Mass spectra were obtained
using a Waters ZQ4000 single quadrupole or a Micromass Ultima
triple quadrupole mass spectrometer. Silica gel (60 Å, 40−63 μm,
Fisher) or cartridges (Biotage snap cartridges KP-SIL or Isolute Si-II
cartridges) were used for ﬂash chromatography. Routine analytical thin
layer chromatography was performed on precoated plates (Alugram,
SILG/UV254). Reverse-phase preparative HPLC was carried out on a
Waters ZQ instrument using mass-directed puriﬁcation on a
preparative C18 column (Phenomenex Luna C18 (2), 100 mm ×
21.2 mm, 5 μm). Depending upon the retention time and the degree
of separation of the desired product from any impurities an A:B
gradient was employed starting from high %A low %B at a ﬂow rate of
20 mL/min. The following combinations of A and B were typically
used: A = H2O + 0.1% formic acid, B = MeOH + 0.1% formic acid, or
A = H2O + 0.1% TFA, B = MeCN + 0.1% TFA, or A = 10 mM
NH4HCO3 (aq), B = MeOH. All compounds tested were at least 95%
pure by LC-MS unless otherwise stated.
In all cases pyruvamide inhibitors of Der p 1 were synthesized by
oxidation of the corresponding α-hydroxyamide (7) using the same
general procedure.
General Procedure I: Oxidation of α-Hydroxyamides (7) to
Pyruvamides. To a stirred solution of 7 (1 equiv) in anhydrous
DCM (1 mL/25−250 mg of alcohol) and anhydrous DMF (10−35%
v/v depending upon solubility) at ambient temperature was added
Dess−Martin periodinane (1.6 equiv) in portions. The reaction
mixture was stirred at ambient temperature and monitored by LC-MS
until full conversion to product pyruvamide had occurred (typically 1
h to 1 day). Where necessary, additional Dess−Martin periodinane
was added to complete the oxidation. The reaction mixture was
quenched by addition of saturated NaHCO3 (aq) (1 volume) and
Na2S2O3 (aq, 10% w/v). The mixture was stirred for ∼30 min, diluted
with ethyl acetate (10 volumes), and washed with saturated NaHCO3
(aq) (2 × 5 volumes), deionized water (5 volumes), and brine (5
volumes). The organic layer was subsequently dried over MgSO4,
ﬁltered, and evaporated. Puriﬁcation by reverse-phase preparative
HPLC was generally followed by lyophilization to give the desired
pyruvamide.
The synthesis of pyruvamide compounds via routes A, B, C, or D
required the synthesis of intermediates 6a−l, 8a−c, 9a, and 15a−i.
The syntheses of these compounds are described in the Supporting
Information.
N-{(S)-1-[(S)-1-((S)-1-Cyclohexylaminooxalyl-pentylcarbamo-
yl)-ethylcarbamoyl]-2-phenyl-ethyl}-benzamide (5). Compound
5 was made using Route A:
N-{1-[(S)-1-((S)-(S)-1-Formyl-pentylcarbamoyl)-ethylcarba-
moyl]-2-phenyl-ethyl}-benzamide (14a). To a solution of acid 6a
(2.0 g, 5.9 mmol) in anhydrous THF (50 mL) at −40 °C was added
N-methylmorpholine (2.0 mL, 18.2 mmol) and i-BuOCOCl (0.8 mL,
6.4 mmol), and the reaction mixture was stirred for 1 h at −40 °C. A
solution of (S)-2-amino-1-hexanol (757 mg, 6.4 mmol) in dry THF (5
mL) was then added dropwise and the reaction mixture stirred at −40
°C for 6 h before warming to room temperature slowly over 1−2 h.
The resulting mixture was diluted with EtOAc (150 mL) and washed
with saturated NaHCO3 (aq) (2 × 100 mL) and brine (1 × 100 mL).
The organic layer was dried over MgSO4, ﬁltered, and evaporated to
give a crude oil. The oil was puriﬁed by ﬂash chromatography on silica,
eluting with EtOAc to 30% MeOH/EtOAc to give a white solid (1.6 g;
MS [M + H]+ 440). The solid was dissolved in anhydrous DCM (40
mL) and anhydrous DMF (8 mL) and Dess−Martin periodinane (1.5
g, 3.4 mmol) was added. The reaction mixture was stirred at ambient
temperature for 4 h and monitored by LC-MS; if the reaction had not
gone to completion, a further amount of Dess−Martin periodinane
was added and the reaction mixture stirred until completion (in this
instance 450 mg, 1.1 mmol was added and the reaction mixture stirred
for a further 2 h). The solvent was removed by evaporation and the
crude mixture redissolved in EtOAc (50 mL). A solution of sodium
thiousulfate in saturated NaHCO3 (aq) (3 g in 30 mL) was added and
the mixture stirred for ∼30 min. The organic layer was separated and
washed with saturated NaHCO3 (aq) (2 × 50 mL) and brine (50 mL)
then dried over MgSO4, ﬁltered, and evaporated to yield a pale-yellow
oil. Trituration with Et2O gave 14a as white solid (683 mg, 26%); [M
+ H]+ 438. 1H NMR ((CD3)2SO, 400 MHz): δ 9.40 (1H, s, C(O)H),
8.58 (1H, d, J = 8.3 Hz, NH), 8.33 (1H, d, J = 7.3 Hz, NH), 8.27 (1H,
d, J = 7.1 Hz, NH), 7.80−7.75 (2H, m, ArH), 7.54−7.49 (1H, m,
ArH), 7.47−7.41 (2H, m, ArH), 7.40−7.35 (2H, m, ArH), 7.29−7.23
(2H, m, ArH), 7.19−7.13 (1H, m, ArH), 4.75−4.68 (1H, m,
CHC(O)), 4.41−4.33 (1H, m, CHC(O)), 4.10−4.03 (1H, m,
CHC(O)), 3.13 (1H, dd, J = 13.9, 4.0 Hz, 1 of CH2Ph), 2.98 (1H,
dd, J = 13.9, 11.1 Hz, 1 of CH2Ph), 1.80−1.61 (1H, m), 1.52−1.44
(1H, m), 1.34−1.22 (7H, m), 0.87−0.82 (3H, m).
Compound 5. To a stirred solution of 14a (218 mg, 0.5 mmol) in
anhydrous DCM (2 mL) at 0 °C was added cyclohexylisonitrile (74
μL, 0.6 mmol) and pyridine (161 μL, 2.0 mmol) followed by dropwise
addition of TFA (74 μL, 1.0 mmol). The reaction mixture was stirred
at 0 °C for 10 min and then allowed to warm to ambient temperature.
After 4 h at room temperature, analytical LC-MS suggested that
considerable starting material remained. Therefore, further cyclo-
hexylisonitrile (61 μL, 0.5 mmol) and TFA (37 μL, 0.5 mmol) was
added and the reaction mixture stirred for 18 h. The mixture was
diluted with DCM (10 mL), washed with saturated NaHCO3 (aq) (2
× 15 mL) and brine (15 mL), and the organic layer then dried over
MgSO4, ﬁltered and evaporated. The crude material was oxidized
following general procedure I to give compound 5 (76 mg, 27%); [M
+ H]+ 563. 1H NMR ((CD3)2SO, 400 MHz): δ 8.58 (1H, d J = 8.6
Hz, NH), 8.55 (1H, d, J = 8.4 Hz, NH), 8.28 (1H, d, J = 7.6 Hz, NH),
8.22 (1H, d, J = 7.1 Hz, NH), 7.80−7.74 (2H, m, ArH), 7.55−7.48
(1H, m, ArH), 7.47−7.41 (2H, m, ArH), 7.40−7.35 (2H, m, ArH),
7.30−7.23 (2H, m, ArH), 7.19−7.14 (1H, m, ArH), 5.00−4.94 (1H,
m, CHCO), 4.76−4.66 (1H, m, CHCO), 4.42−4.34 (1H, m, CHCO),
3.60−3.50 (1H, m, NHCH(cyclohexyl)), 3.12 (1H, dd, J = 13.8 and
3.4 Hz, 1 of CH2Ph), 2.96 (1H, dd, J = 13.8 and 11.2 Hz, 1 of CH2Ph),
1.80−1.40 (7H, m), 1.39−1.00 (12H, m), 0.82 (3H, t, J = 6.9 Hz,
CH3).
((S)-2-Cyano-2-hydroxy-1-isopropyl-ethyl)-carbamic Acid
Benzyl Ester (17). To Cbz-Val-OH (16) (50.0 g, 199 mmol), N,O-
dimethylhydroxylamine hydrochloride (38.8 g, 398 mmol) and EDC·
HCl (47.7 g, 249 mmol) in DCM (500 mL) was added DIPEA (87
mL, 497 mmol), and the reaction mixture stirred at ambient
temperature for 20 h, after which time it was diluted with DCM
(200 mL), washed with 1 M HCl (aq) (3 × 200 mL), 1 M NaOH (aq)
(200 mL), saturated NaHCO3 (aq) (200 mL), and brine (300 mL).
The organic layer was dried over MgSO4, ﬁltered, and the solvent
removed under vacuum to give the desired compound as a colorless oil
(51.2 g; MS [M + H]+ 295). A portion of this (33 g, ∼112 mmol) was
dissolved in anhydrous THF (300 mL) at −30 to −40 °C, and LiAlH4
(4.3 g, 113 mmol) was added portionwise over a period of 45 min.
The mixture was warmed to 0 °C and stirred for 2 h. The reaction
mixture was quenched at 0 °C with 1 M KHSO4 (330 mL) then 10%
w/v Rochelle’s salt (aq) (330 mL) was added and the mixture stirred
for 20 min then extracted with EtOAc (2 × 700 mL). The combined
organic phases were washed with 10% w/v Rochelle’s salt (aq) (330
mL) and brine (450 mL), dried over MgSO4, ﬁltered, and
concentrated under vacuum to obtain a clear oil (26.3 g, major
peak; [M + H]+ 236). The oil was dissolved in MeOH (150 mL) and
cooled to 0 °C. A solution of NaHSO3 (11.9 g, 114 mmol) in H2O
(230 mL) was added and the mixture stirred at 0 °C for 2.5 h. The
resulting mixture was added to a solution of NaCN (8.5 g, 174 mmol)
in H2O (150 mL) and EtOAc (450 mL) also at 0 °C. After 1 h, this
was allowed to warm to ambient temperature and was stirred for 20 h.
The EtOAc layer was separated and the aqueous layer extracted with
EtOAc (2 × 500 mL). The combined organic extracts were washed
with brine (400 mL), dried over MgSO4, ﬁltered, and concentrated to
give compound 17 (29.7 g, crude, ∼ 1:1 mixture of diastereomers) as a
clear gummy liquid; [M + H2O]
+ 280. The mixture was used without
further puriﬁcation in the synthesis of 18.
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(S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-methyl-penta-
noic Acid (18). To a solution of 18 (5.1 g, 19.5 mmol) in 1,4-dioxane
(90 mL) was added concentrated HCl (aq) (90 mL) and anisole (1.5
equiv), and the mixture was heated to 110 °C for 18 h. The reaction
mixture was cooled to ambient temperature and concentrated under
vacuum to remove the dioxane. The mixture was then washed with
EtOAc, and the residue was further concentrated under vacuum at 40
°C to remove the HCl (aq). Residual water was removed by
azeotroping with toluene. The residue was washed with Et2O (2 × 50
mL) to give a gummy solid. The crude mixture was dissolved in
methanol (100 mL), and Et3N (9.0 mL, 64 mmol) was added. Di-tert-
butyl dicarbonate (4.7 g, 22 mmol, ∼1.1 equiv based upon crude solid)
was added portionwise, and the reaction mixture was stirred at
ambient temperature for 20 h. The reaction mixture was concentrated
in vacuo, and the residue was dissolved in EtOAc (100 mL) and 1N
NaOH (aq) (75 mL). The organic phase was separated, and the
aqueous phase was washed further with EtOAc (2 × 100 mL) to
remove any nonpolar/nonacidic impurities. The aqueous layer was
then acidiﬁed (pH ∼2) with 2 N HCl and extracted with EtOAc (3 ×
100 mL). The combined organic phases were dried over MgSO4,
ﬁltered, and concentrated under vacuum to give a white, waxy solid.
This was further puriﬁed on a Biotage Isolute (IST)-NH2 cartridge (25
g/150 mL). The cartridge was ﬁrst equilibrated with MeOH (75 mL),
MeCN (75 mL) and EtOAc (75 mL). The crude mixture was then
loaded in 5% MeOH/EtOAc (50 mL) and washed with EtOAc (2 ×
75 mL) and MeCN (75 mL). The desired mixture of diastereomeric
acids was then eluted by washing with MeCN containing 1% formic
acid (350 mL). A 1:1 diastereomeric mixture of the desired
compounds was obtained, as a white solid, following evaporation of
the solvent under vacuum (1.5 g, 27% from compound 16). 18A: [M
− H]− 246; 1H NMR ((CD3)2SO, 400 MHz): δ 12.4 (1H, br s), 6.46
(1H, d, J = 10.0 Hz), 5.38 (1H, br s), 3.83 (1H, d, J = 6.8 Hz), 3.65−
3.59 (1H, m), 1.99−1.91 (1H, m), 1.36 (9H, s), 0.81−0.76 (6H, m).
18B: MS [M − H]− 246; 1H NMR ((CD3)2SO, 400 MHz): δ 12.44
(1H, br s), 6.21 (1H, d, J = 10.0 Hz), 4.95 (1H, br s), 4.11 (1H, d, J =
1.6 Hz), 3.53−3.47 (1H, m), 1.74 (1H, m), 1.35 (9H, s), 0.91−0.83
(6H, m). The single diastereomer 18A could be isolated by dissolving
the mixture of diastereomers in CHCl3 and adding n-pentane to aﬀord
isomer 18A as a white precipitate that could be collected by ﬁltration.
N-{(S)-1-[(S)-1-((S)-1-Cyclohexylaminooxalyl-2-methyl-pro-
pylcarbamoyl)-ethylcarbamoyl]-2,2-dimethyl-propyl}-benza-
mide (22). Compound 22 was prepared as a white solid from
compound 6b (17 mg, 10%) using a similar procedure to that of
compound 5, with the exception that the aldehyde intermediate was
puriﬁed by reverse-phase preparative HPLC using a H2O + 0.1%
TFA/MeCN + 0.1% TFA gradient at 50 °C followed by lyophilization
to remove the solvent. [M + H]+ 515. 1H NMR ((CD3)2SO, 400
MHz): δ 8.53 (1H, d, J = 8.1 Hz, NH), 8.19 (1H, d, J = 7.1 Hz, NH),
7.98 (1H, d, J = 7.8 Hz, NH), 7.88 (1H, d, J = 9.2 Hz, NH), 7.86−7.82
(2H, m, ArH), 7.58−7.52 (1H, m, ArH), 7.50−7.44 (2H, m, ArH),
5.04 (1H, dd, J = 7.8, 5.3 Hz, CHCO), 4.50 (1H, d, J = 9.2 Hz,
CHCO), 4.49−4.41 (1H, m, CHCO), 3.61−3.50 (1H, m, NHCH-
(cyclohexyl)), 2.22−2.12 (1H, m, CHMe2), 1.73−1.63 (4H, m),
1.61−1.52 (1H, m), 1.34−1.19 (7H, m), 1.14−1.02 (1H, m), 1.00
(9H, s, t-Bu) 0.89 (3H, d, J = 6.8 Hz, CH3), 0.81 (3H, d, J = 6.8 Hz,
CH3).
Quinoline-4-carboxylic Acid {(S)-1-[(S)-1-((S)-1-Benzylami-
nooxalyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-2,2-di-
methyl-propyl}-amide (27). Compound 27 was prepared as a white
solid from compound 6c (32 mg, 62%) using a similar procedure to
that of 22; [M + H]+ 574. 1H NMR ((CD3)2SO, 400 MHz): δ 9.30
(1H, t, J = 6.3 Hz, NH), 8.96 (1H, d, J = 4.3 Hz, ArH), 8.72 (1H, d, J
= 9.0 Hz, NH), 8.21 (1H, d, J = 6.8 Hz, NH), 8.12 (1H, d, J = 7.8 Hz,
NH), 8.08 (1H, d, J = 7.8 Hz, ArH), 8.05 (1H, dd, J = 8.3 Hz, 0.8 Hz,
ArH), 7.84−7.78 (1H, m, ArH), 7.68−7.62 (1H, m, ArH), 7.48 (1H,
d, J = 4.3 Hz, ArH), 7.35−7.29 (2H, m, ArH), 7.28−7.22 (3H, m,
ArH), 5.06 (1H, dd, J = 7.8, 5.4 Hz, CHCO), 4.47 (1H, d, J = 9.0 Hz,
CHCO), 4.54−4.45 (1H, m, CHCO), 4.36 (1H, dd, J = 14.7, 6.3 Hz, 1
of CH2Ph), 4.30 (1H, dd, J = 14.7, 6.3 Hz, 1 of CH2Ph), 2.25−2.16
(1H, m, CHMe2), 1.24 (3H, d, J = 7.1 Hz, CH3), 1.03 (9H, s, t-Bu),
0.91 (3H, d, J = 6.8 Hz, CH3), 0.84 (3H, d, J = 6.8 Hz, CH3).
(S)-3-{(S)-2-[(S)-3,3-Dimethyl-2-(1-oxo-1,3-dihydro-isoindol-
2-yl)-butyrylamino]-propionylamino}-4-methyl-2-oxo-penta-
noic Acid Benzylamide (28). To a solution of 6d (350 mg, 1.1
mmol) in anhydrous THF (10 mL) at −40 °C was added N-
methylmorpholine (240 μL, 2.1 mmol) and i-BuOCOCl (180 μL, 1.2
mmol) and the reaction mixture stirred for 1 h. A solution of
compound 15a (420 mg, 1.2 mmol) in dry THF (5 mL) and N-
methylmorpholine (180 μL, 1.6 mmol) was then added dropwise and
the reaction mixture stirred at −40 °C for 6 h before warming to room
temperature over 1−2 h. The solvent was evaporated in vacuo and the
crude residue dissolved in EtOAc (50 mL) then washed with saturated
NaHCO3 (aq) (2 × 50 mL) and brine (50 mL). The organic layer was
dried over MgSO4, ﬁltered, and evaporated to give a white solid.
Oxidation using general procedure I gave compound 28 as a white
solid (277 mg, 47%); [M + H]+ 535. 1H NMR ((CD3)2SO, 400
MHz): δ 9.29 (1H, t, J = 6.5 Hz, NH), 8.52 (1H, d, J = 6.8 Hz, NH),
7.99 (1H, d, J = 7.7 Hz, NH), 7.71 (1H, d, J = 7.6 Hz, ArH), 7.64−
7.56 (2H, m, ArH), 7.52−7.46 (1H, m, ArH), 7.35−7.29 (2H, m,
ArH), 7.28−7.22 (3H, m, ArH), 5.05 (1H, dd, J = 7.7, 5.5 Hz,
CHCO), 5.00 (1H, d, J = 18.4 Hz, 1 from dihydro-isoindolone ring),
4.84 (1H, s, CHCO), 4.76 (1H, d, J = 18.4 Hz, 1 from dihydro-
isoindolone ring), 4.40−4.27 (3H, m, CH2Ph and CHCO), 2.26−2.14
(1H, m, CHMe2), 1.16 (3H, d, J = 7.1 Hz, CH3), 1.05 (9H, s, t-Bu),
0.92 (3H, d, J = 6.8 Hz, CH3), 0.83 (3H, d, J = 6.8 Hz, CH3).
N-{(S)-1-[(S)-1-((S)-1-Cyclohexylaminooxalyl-2-methyl-pro-
pylcarbamoyl)-ethylcarbamoyl]-2,2-dimethyl-propyl}-isonico-
tinamide (29). Compound 29 was prepared as a white solid from
compound 6e (59 mg, 5%) using a similar procedure to that of 22; [M
+ H]+ 516. 1H NMR ((CD3)2SO, 400 MHz): δ 8.75−8.72 (2H, m,
ArH), 8.57 (1H, d, J = 8.3 Hz, NH), 8.38 (1H, d, J = 9.4 Hz, NH),
8.24 (1H, d, J = 7.1 Hz), 8.02 (1H, d, J = 7.8 Hz, NH), 7.81−7.78
(2H, m, ArH), 5.04 (1H, dd, J = 7.8 and 5.3 Hz, CHCO), 4.52 (1H, d,
J = 9.4 Hz, CHCO), 4.47−4.40 (1H, m, CHCO), 3.60−3.45 (1H, m,
NHCH(cyclohexyl), 2.22−2.12 (1H, m, CHMe2), 1.72−1.64 (4H, m),
1.61−1.54 (1H, m), 1.34−1.17 (7H, m), 1.12−1.04 (1H, m), 1.00
(9H, s, t-Bu), 0.89 (3H, d, J = 6.8 Hz, CH3), 0.80 (3H, d, J = 6.8 Hz,
CH3).
4-{(S)-1-[(S)-1-((S)-1-Benzylaminooxalyl-2-methyl-propylcar-
bamoyl)-ethylcarbamoyl]-2,2-dimethyl-propylcarbamoyl}-1,1-
dimethyl-piperidinium Formate (32). Compound 32 was prepared
in its formate salt form from compounds 6f and 15a (19 mg, 20%)
using a similar procedure to that of compound 28, yielding a white
solid; [M]+ 558. 1H NMR ((CD3)2SO, 400 MHz): δ 9.31 (1H, t, J =
6.3 Hz, NH), 8.42 (1H, s HC(O)O− from formate), 8.25 (1H, d, J =
6.8 Hz, NH), 8.13 (1H, d, J = 9.8 Hz), 8.09 (1H, J = 7.8 Hz, NH),
7.35−7.28 (2H, m, ArH), 7.28−7.21 (3H, m, ArH), 5.05 (1H, dd, J =
7.8, 5.3 Hz, CHCO), 4.41−4.23 (4H, m, CH2Ph and 2 × CHCO),
3.40−3.20 (4H, m, Me2N+(CH2)2−), 3.12 (3H, s, +NCH3), 3.02 (3H,
s, +NCH3), 2.60−2.55 (1H, m, piperidine ring adjacent to C(O)NH),
2.24−2.14 (4H, m, piperidine ring), 1.18 (3H, d, J = 7.0 Hz, CH3),
0.93−0.87 (12H, m, t-Bu and CH3), 0.82 (3H, d, J = 6.8 Hz, CH3).
N-{(S)-1-[(S)-1-((S)-1-Benzylaminooxalyl-2-methyl-propylcar-
bamoyl)-ethylcarbamoyl]-2,2-dimethyl-propyl}-benzamide
(38). Compound 38 was prepared from compounds 6b and 15a, as a
white solid (170 mg, 50%) using a similar procedure to that of 28; [M
+ H]+ 523. 1H NMR ((CD3)2SO, 400 MHz): δ 9.24 (1H, t, J = 6.3
Hz, NH), 8.18 (1H, d, J = 7.1 Hz, NH), 8.13 (1H, d, J = 7.8 Hz, NH),
7.88 (1H, d, J = 9.5 Hz, NH), 7.86−7.82 (2H, m, ArH), 7.57−7.52
(1H, m, ArH), 7.50−7.45 (2H, m, ArH), 7.35−7.29 (2H, m, ArH),
7.27−7.22 (3H, m, ArH), 5.03 (1H, dd, J = 7.8, 5.6 Hz, CHCO), 4.50
(1H, d, J = 9.5 Hz, CHCO), 4.49−4.40 (1H, m, CHCO), 4.38−4.26
(2H, m, CH2Ph), 2.25−2.15 (1H, m, CHMe2), 1.20 (3H, d, J = 7.1
Hz, CH3), 1.01 (9H, s, t-Bu), 0.89 (3H, d, J = 6.8 Hz, CH3), 0.82 (3H,
d, J = 6.8 Hz, CH3).
N-[(S)-1-((S)-1-{(S)-2-Methyl-1-[2-(4-methyl-piperazin-1-yl)-2-
oxo-ethylaminooxalyl]-propylcarbamoyl}-ethylcarbamoyl)-2-
phenyl-ethyl]-benzamide (45). Compound 45 was prepared as its
TFA salt and was isolated as a white solid from compound 6a (16 mg,
14%) using a similar procedure to that of 22; [M + H]+ 607. 1H NMR
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((CD3)2SO, 400 MHz): δ 9.80 (1H, s, MeN
+H), 8.71 (1H, t, J = 5.7
Hz, NH), 8.58 (1H, d, J = 8.3 Hz, NH), 8.32 (1H, d, J = 7.1 Hz, NH),
8.09 (1H, d, J = 7.6 Hz, NH), 7.79−7.75 (2H, m, ArH), 7.54−7.49
(1H, m, ArH), 7.47−7.41 (2H, m, ArH), 7.40−7.36 (2H, m, ArH),
7.29−7.23 (2H, m, ArH), 7.19−7.13 (1H, m, ArH), 5.08 (1H, dd, J =
7.6, 5.1 Hz, CHCO), 4.75−4.68 (1H, m, CHCO), 4.50−4.30 (2H, m,
CHCO + 1 other), 3.15−2.90 (3H, m), 3.50−3.30 (4H, m partially
obscured by HOD residual), 3.15−2.90 (4H, m, CH2Ph + 2 others),
2.82 (3H, s, NCH3), 2.26−2.16 (1H, m, CHMe2), 1.26 (3H, d, J = 7.1
Hz, CH3), 0.91 (3H, d, J = 6.8 Hz, CH3), 0.83 (3H, d, J = 6.8 Hz,
CH3).
N-((S)-1-{(S)-1-[(S)-2-Methyl-1-(2-morpholin-4-yl-2-oxo-eth-
ylaminooxalyl)-propylcarbamoyl]-ethylcarbamoyl}-2-phenyl-
ethyl)-benzamide (47). Compound 47 was prepared as a white solid
from compound 6a (8 mg, 5%) using a similar procedure to that of 22;
[M + H]+ 594. 1H NMR ((CD3)2SO, 400 MHz): δ 8.62 (1H, t, J = 5.8
Hz, NH), 8.58 (1H, d, J = 8.3 Hz, NH), 8.32 (1H, d, 7.3 Hz, NH),
8.08 (1H, d, J = 7.8 Hz, NH), 7.79−7.75 (2H, m, ArH), 7.54−7.48
(1H, m, ArH), 7.46−7.41 (2H, m, ArH), 7.40−7.36 (2H, m, ArH),
7.29−7.23 (2H, m, ArH), 7.18−7.13 (1H, m, ArH), 5.06 (1H, dd, J =
7.8, 5.3 Hz, CHCO), 4.75−4.68 (1H, m, CHCO), 4.50−4.40 (1H, m,
CHCO), 4.04 (1H, dd, J = 16.7, 5.8, 1 of CH2CO-morpholine), 3.98
(1H, dd, J = 16.7, 5.8, 1 of CH2CO-morpholine), 3.60−3.52 (4H, m,
morpholine), 3.45−3.39 (4H, m, morpholine), 3.12 (1H, dd, J = 13.6,
3.4 Hz, 1 of CH2Ph), 2.97 (1H, dd, J = 13.6, 11.3 Hz, 1 of CH2Ph),
2.27−2.17 (1H, m, CHMe2), 1.26 (3H, d, J = 7.1 Hz, CH3), 0.90 (3H,
d, J = 6.8 Hz, CH3), 0.83 (3H, d, J = 7.1 Hz, CH3).
4-(2-{(S)-3-[(S)-2-((S)-2-Benzoylamino-3-phenyl-propionyla-
mino)-propionylamino]-4-methyl-2-oxo-pentanoylamino}-
acetyl)-1,1-dimethyl-piperazin-1-ium Formate (52). Compound
52 was prepared as its formate salt and isolated as a white solid (40
mg, 37%) from compounds 6a and 15b using a similar procedure to
that of 28; [M]+ 621. 1H NMR ((CD3)2SO, 400 MHz): δ 8.78 (1H, t,
J = 5.7 Hz, NH), 8.69 (1H, d, J = 8.6 Hz, NH), 8.49 (1H, d, J = 7.3 Hz,
NH), 8.47 (1H, s, HC(O)O−), 8.15 (1H, d, J = 7.6 Hz, NH), 7.82−
7.76 (2H, m, ArH), 7.534−7.48 (1H, m, ArH), 7.46−7.41 (2H, m,
ArH), 7.40−7.35 (2H, m, ArH), 7.29−7.23 (2H, m, ArH), 7.18−7.13
(1H, m, ArH), 5.07 (1H, dd, J = 7.6, 5.2 Hz, CHCO), 4.76−4.68 (1H,
m, CHCO), 4.49−4.39 (1H, m, CHCO), 4.12 (1H, dd, J = 16.9, 5.7
Hz, 1 of CH2CO), 4.07 (1H, dd, J = 16.9, 5.7 Hz, 1 of CH2CO),
3.86−3.74 (4H, m, piperazine ring), 3.44−3.34 (2H, m, piperazine
ring), 3.20−3.09 (8H, m, including N+(CH3)2), 3.04−2.92 (2H, m),
2.26−2.16 (1H, m, CHMe2), 1.27 (3H, d, J = 7.1 Hz, CH3), 0.91 (3H,
d, J = 6.8 Hz, CH3), 0.83 (3H, d, J = 6.8 Hz, CH3).
Naphthalene-1-carboxylic Acid [(S)-1-((S)-1-{(S)-2-Methyl-1-
[2-(4-methyl-piperazin-1-yl)-2-oxo-ethylaminooxalyl]-propyl-
carbamoyl}-ethylcarbamoyl)-2-phenyl-ethyl]-amide (53). Com-
pound 53 was prepared as its TFA salt and was isolated as a white
solid (30 mg, 18%) from compounds 6g and 15c using a similar
procedure to that of 28; [M + H]+ 657. 1H NMR ((CD3)2SO, 400
MHz): δ 9.80 (1H, br s, MeN+H), 8.76−8.69 (2H, m), 8.29 (1H, d, J
= 7.1 Hz), 8.17 (1H, d, J = 7.6 Hz), 7.97 (1H, d, J = 8.3 Hz), 7.93 (1H,
d, J = 8.1 Hz), 7.74 (1H, d, J = 8.1 Hz), 7.54−7.47 (2H, m, ArH),
7.44−7.36 (4H, m, ArH), 7.35−7.29 (2H, m, ArH), 7.29−7.22 (1H,
m, ArH), 5.09 (1H, dd, J = 7.6, 5.0 Hz, CHCO), 4.90−4.82 (1H, m,
CHCO), 4.57−4.47 (1H, m, CHCO), 4.46−4.30 (1H, m), 4.22−3.92
(3H, m), 3.30−2.78 (7H, m), 2.79 (3H, s, NCH3), 2.27−2.17 (1H, m,
CHMe2), 1.30 (3H, d, J = 7.1 Hz, CH3), 0.91 (3H, d, J = 6.8 Hz,
CH3), 0.84 (3H, d, J = 6.8 Hz, CH3) also 1 × H under HOD 3.40−
3.20 ppm.
Group 1 HDM Peptidase Allergen Inhibition Assays.
Automated screening of inhibitory activity toward group 1 HDM
peptidase allergens was performed as described elsewhere25,43 with the
minor modiﬁcation that Der p 1 or Der f 1 were incubated with
inhibitors for 20 min prior to initiation of reactions by addition of
substrate. In initial screening, the activity of each compound was
measured using a series of 10 doubling dilutions from a starting
concentration of 50 μM. Compounds showing optimizable activity
were cherry-picked for multiple (up to six) rounds of rescreening to
conﬁrm activity and stability and to determine IC50 values over a range
of concentrations that were compound-directed by initial screening.
Assays were performed in triplicate for calculation of mean ± SE IC50
values.
Cathepsin Inhibition Assays. Oﬀ-target screening adopted the
same principles as target potency determination. Inhibition of Cat B
was measured as described with modiﬁcations.25 Reaction mixtures
comprised 10 μL of human liver Cat B (0.5 nM ﬁnal concentration,
Merck Chemicals Ltd. UK) preactivated by 2.5 mM 1,4-dithioery-
thritol (DTE, Sigma-Aldrich) at 37 °C for 10 min, 70 μL of reaction
buﬀer (0.1 M NaAc-HAc, pH 4.5, 0.2 M NaCl), and 10 μL of 22.5
mM DTE (2.5 mM ﬁnal concentrations). Reactions were initiated by
adding 10 μL of 59 μM substrate ABz-Gly-Ile-Val-Arg-Ala-Lys-DNP-
OH (Merck Chemicals Ltd., UK) dissolved in reaction buﬀer. Progress
curves were followed at 30 °C by detection of ﬂuorescence at 320/420
nm (excitation/emission).
To test inhibitory potential against Cat S, reaction mixtures
comprised 70 μL of reaction buﬀer (0.1 M sodium phosphate/2 mM
EDTA, pH 7.4), 10 μL of recombinant human Cat S (25 nM in
reaction buﬀer and 10 μL DTT (2 mM ﬁnal concentration). Reactions
were initiated by addition of 10 μL of substrate (Z-Phe-Arg-AMC, 20
μM ﬁnal concentration in assay). Reactions were performed at 30 °C
and progress followed by excitation/emission at 320/420 nm.
In all cases, for reactions involving inhibitors, the amount of
reaction buﬀer was adjusted to 60 μL, the inhibitor added as a 10 μL
aliquot, and incubated for 20 min with the enzyme prior to reaction
start.
Counter-screening against a broader range of proteases, with
exempliﬁcation for compound 38, is described in Appendix 7 of the
Supporting Information.
Allergen Challenge. Brown Norway strain rats (male, 300−350 g
at time of allergen challenge, 12−16 weeks old, Harlan UK Ltd.) were
used to explore the pharmacological properties of ADIs. To examine
the relationship between the physicochemical properties of com-
pounds and their duration of protection through the intended
mechanism of action, animals were used without prior sensitization
to HDM so that allergen challenge activated only IgE-independent
innate mechanisms.
For other studies, rats were actively sensitized to a natural mixture
of HDM allergens prepared from laboratory cultures of Dermatopha-
goides pteronyssinus. Animals were sensitized by the ip route in the
absence of additional adjuvant on day 0, 7, and 14. This protocol is
known to result in the development of allergic sensitization as judged
by the appearance of allergen-speciﬁc IgE. For standardization
purposes, sensitization mixtures were normalized to contain 10 μg
Der p 1 of known catalytic activity, as previous studies indicated that
this yielded satisfactory adjuvantless responses. Negative control
groups comprised naiv̈e, unsensitized animals or those sham-sensitized
with vehicle solution.
Test ADIs were delivered as intratracheal aerosols of 25−30 μm
mass median diameter from a Penn-Century IA-1B microsprayer at
various times prior to allergen challenge. Allergen or vehicle challenge
was similarly delivered by Penn-Century microsprayer on day 21 of the
protocol. These procedures were conducted under anesthesia with
isoﬂurane in oxygen. Test ADIs were generally dosed in a constant
50:1 molar ratio to the Der p 1 content of the allergen challenge
mixture. In practice, this resulted in doses of 35−45 μg/kg being
delivered to animals, except in the case of compound 38, where the
maximum dose used was 12 μg/kg (20 nmol/kg).
All in vivo studies were conducted within the jurisdiction of, and in
accordance with, the UK Animals (Scientiﬁc Procedures) Act, 1986, in
an AAALAC-accredited facility. Groups typically comprised 10 animals
randomly assigned to treatment. Treatments were coded prior to
formulation so that staﬀ responsible for dosing were unaware of test
substance identity.
Pulmonary Leukocyte Accumulation. Animals were killed by
sodium pentobarbital overdose 48 h after allergen challenge because
this is the optimal sampling point to assess the recruitment of
eosinophils (our unpublished observations). The airways were lavaged
with 3 × 4 mL aliquots of Hanks’ Balanced Salt Solution and the
recovered cells pooled and counted automatically (ADVIA; Bayer
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Healthcare, Diagnostics Division, UK). Diﬀerential counts were
obtained after the preparation of smears by cytocentrifugation and
the staining of methanol-ﬁxed cells with buﬀered eosin and methylene
blue/azur 2 (Speedy-Diﬀ; ClinTech Ltd., Guildford, Surrey UK). Cells
were counted by an independent observer using light microscopy
under oil immersion (×1000). Statistical analyses of cell data were
made by one-way ANOVA and Holm−Sidak test.
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